Literature DB >> 21406216

Whole body cholesterol metabolism is impaired in Huntington's disease.

V Leoni1, C Mariotti, L Nanetti, E Salvatore, F Squitieri, A R Bentivoglio, M Bandettini di Poggio, M Bandettini Del Poggio, S Piacentini, D Monza, M Valenza, E Cattaneo, S Di Donato.   

Abstract

We previously reported impaired cholesterol biosynthesis in rodent Huntington Disease (HD) models and HD patients' fibroblasts and post mortem brains. We also found that plasma levels of 24S-hydroxycholesterol (24OHC), the brain specific elimination product of cholesterol considered a marker of brain cholesterol turnover, were significantly reduced in HD patients at any disease stage. In the present study we analysed by mass spectrometry the fasting plasma levels of cholesterol, its biosynthetic precursors lanosterol and lathosterol, of the whole-body elimination products 27-hydroxycholesterol and of brain 24OHC in a cohort of premanifest and HD patients at different disease stages. We found that the cholesterol precursors lanosterol and lathosterol (both index of whole body cholesterol synthesis), the levels of the bile acid precursor 27-hydroxycholesterol, and of the brain specific 24OHC, were all significantly reduced in manifest HD patients, suggesting that whole-body and brain cholesterol homeostasis are both impaired in HD.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21406216     DOI: 10.1016/j.neulet.2011.03.025

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  28 in total

1.  Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.

Authors:  Eugenia Trushina; Christie A Canaria; Do-Yup Lee; Cynthia T McMurray
Journal:  Hum Mol Genet       Date:  2013-09-10       Impact factor: 6.150

Review 2.  24(S)-Hydroxycholesterol as a Modulator of Neuronal Signaling and Survival.

Authors:  Min-Yu Sun; Andrew J Linsenbardt; Christine M Emnett; Lawrence N Eisenman; Yukitoshi Izumi; Charles F Zorumski; Steve Mennerick
Journal:  Neuroscientist       Date:  2015-01-27       Impact factor: 7.519

3.  Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations.

Authors:  Valerio Leoni; Laura Strittmatter; Giovanna Zorzi; Federica Zibordi; Sabrina Dusi; Barbara Garavaglia; Paola Venco; Claudio Caccia; Amanda L Souza; Amy Deik; Clary B Clish; Marco Rimoldi; Emilio Ciusani; Enrico Bertini; Nardo Nardocci; Vamsi K Mootha; Valeria Tiranti
Journal:  Mol Genet Metab       Date:  2011-12-14       Impact factor: 4.797

Review 4.  Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.

Authors:  Alexey M Petrov; Irina A Pikuleva
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 5.  Cholesterol metabolism in Huntington disease.

Authors:  Joanna M Karasinska; Michael R Hayden
Journal:  Nat Rev Neurol       Date:  2011-09-06       Impact factor: 42.937

6.  Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients.

Authors:  Alana C Costa; Helena P G Joaquim; Valéria S Nunes; Daniel S Kerr; Guilherme S Ferreira; Orestes V Forlenza; Wagner F Gattaz; Leda Leme Talib
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08-31       Impact factor: 5.270

7.  Cholesterol Modifies Huntingtin Binding to, Disruption of, and Aggregation on Lipid Membranes.

Authors:  Xiang Gao; Warren A Campbell; Maxmore Chaibva; Pranav Jain; Ashley E Leslie; Shelli L Frey; Justin Legleiter
Journal:  Biochemistry       Date:  2015-12-22       Impact factor: 3.162

8.  Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression.

Authors:  Valerio Leoni; Jeffrey D Long; James A Mills; Stefano Di Donato; Jane S Paulsen
Journal:  Neurobiol Dis       Date:  2013-04-01       Impact factor: 5.996

9.  Altered expression of 3-betahydroxysterol delta-24-reductase/selective Alzheimer's disease indicator-1 gene in Huntington's disease models.

Authors:  Athina Samara; Mariarita Galbiati; Paola Luciani; Cristiana Deledda; Elio Messi; Alessandro Peri; Roberto Maggi
Journal:  J Endocrinol Invest       Date:  2014-06-11       Impact factor: 4.256

Review 10.  Mechanism(s) of alteration of micro RNA expressions in Huntington's disease and their possible contributions to the observed cellular and molecular dysfunctions in the disease.

Authors:  Mithun Sinha; Saikat Mukhopadhyay; Nitai P Bhattacharyya
Journal:  Neuromolecular Med       Date:  2012-05-13       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.